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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not 
Necitumumab is an effective add on treatment to traditional chemotherapy regimes when treating
stage IV lung or colon cancer.
Study Designs: Review of two open label, randomized, controlled phase III trials and one single 
arm multicenter phase II study.
Outcomes Measured: Objective tumor response rate was measured for patients with colon 
cancer. Overall survival rate and length of survival were measured for patients with lung cancer. 
This was measured in Kapler Meier Methodology. 
Results: For two trials the addition of Necitumumab improved overall survival and tumor 
response rate. The first lung cancer trial did not show improvement of survival rate with 
Necitumumab. In this trial those receiving the experimental drug had a median survival of 11.3 
months compared to 11.5 in those not receiving the experimental medicine. The second lung 
cancer trial saw survival times as 11.5 months with Necitumumab compared to 9.9 months 
without it. In the third trial all patients were given Necitumumab in addition to FOLFOX agents 
for colon cancer. Tumor response rate was compared between those with a KRAS wildtype gene 
mutation and those with a KRAS mutant gene mutation. The results showed a higher tumor 
response rate for those with the wildtype mutation, however both groups saw positive reduction 
in tumors. 
Conclusion: The addition of Necitumumab to traditional chemotherapy regimes is an effective 
way to fight stage IV cancer, especially in those with a KRAS wildtype mutation or with 
squamous non-small cell lung cancer. It is less effective for non-squamous non-small cell lung 
cancer.
Key Words: Lung Cancer, Colon Cancer, Necitumumab, Stage IV, metastasis, chemotherapy
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INTRODUCTION
Stage IV cancer is often a grave diagnosis for patients. It conjures thoughts of suffering, 
radiation, and weight loss. As clinicians we must take great care in how we approach managing 
care for these patients. Optimizing quality of life, managing expectations, and trying our best to 
fight the spread of tumors are among our goals. Treatment options range from chemotherapy and 
radiation to surgical excision. An entire field of medicine has been created to fight cancer and we
now have fantastic treatment centers and talented specialists across the country. Despite this 
when a patient presents for the first time and is diagnosed with late stage disease it is extremely 
rare to see a full recovery. At this stage of the disease our focus is often on prolonging the 
patients time with us and assuring they maintain a high quality of life while going through 
treatment. For this reason there are ever evolving chemotherapy regiments being researched and 
put into trial. 
This paper aims to discuss three separate of such chemotherapy trials. The drug in 
question is called Necitumumab. It is an epithelial growth factor receptor monoclonal antibody. 
This drug seeks to bind to protein growth factors expressed in tumors and target them for 
destruction by our immune system. It is a novel medicine because previous chemotherapeutic 
agents were created using a combination of mouse and human DNA. Necitumumab is created 
using only human DNA, thus increasing the chance that our bodies will recognize it as “self” and
allow it to bind to tumors more effectively2. The new medicine is being manufactured under the 
brand name Portrazza.
The topic of treating late stage cancer is extremely relevant to the practice of Physician 
Assistants across our country. Not only is Oncology a massive area of research and clinical 
practice, PA’s are playing an increasingly important role in this specialty. They possess all of the 
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clinical tools needed to be an effective part of an Oncology team. In 2013 there were 212,584 
new cases of lung cancer in this country and 156,176 deaths from this disease6. Costs associated 
with a diagnosis like this are astronomical. Some estimates put the costs as high as 90,000 per 
patient in order to get treatment1. It is for these reasons that finding more effective and efficient 
ways to handle late stage cancer is relevant both to PAs and for the medical community in 
general. 
Research into this disease is extensive. It is thought that the origins of tumors are in 
defective gene expression and the cell cycle. Malignant tumors are pieces of tissue which 
essentially have rapid cell turnover resulting in an imbalance between cell creation and cell 
death. This leads to tumor growth and masses forming within the body. The mechanics of tumor 
growth have their origins in genetics. There are several contributing factors which add to the 
development of either lung or colon cancer. The leading cause of lung cancer is tobacco smoke. 
There are massive scale campaigns across the world to encourage smoking cessation and prevent
youth from starting the habit. It is often thought that a contributing factor to colon cancer is the 
“Western diet”. This is a diet high in carbohydrates and low in insoluble fiber4. Nutrition 
campaigns seek to educate the public on the importance of eating a balanced diet not only for the
reason of nutritional sufficiency, but also as a preventive measure for serious diseases such as 
colon cancer.    
Treatment regiments for cancer include chemotherapy, radiation, surgical excision, or a 
combination of all three. It is the judgement call of the clinical team and the patient as to which 
combination of treatment will be most beneficial. Chemotherapy for lung cancer almost always 
includes a platinum agent such as Cisplatin and one other additional medication. For squamous 
cell lung cancer Gemcitibine is usually added while for non-squamous cell Pemetrexed is the 
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additional agent of choice. Colon cancer has been shown to respond best to FOLFOX agents4. 
Portrazza is being proposed as a new agent of add-on treatment because of it is made using only 
human DNA and is thought to be more effective in activating our immune system to attack tumor
cells. 
OBJECTIVE
The objective of this selective EBM review is to determine whether or not Portrazza is an
effective add on treatment to traditional chemotherapy regiments when treating stage IV lung or 
colon cancer.
The populations studied in these trials were composed of individuals over the age of 18 
who had histologically confirmed squamous non-small cell, non-squamous non-small cell, or 
colorectal carcinoma. All individuals in the trials had to have either late stage (III or IV) or 
metastatic disease. The intervention used on these patients was adding Portrazza to their 
chemotherapy regime. For the trials involving pulmonary structures average time of survival 
after initiation of treatment was the measured outcome. This was measured using Kaplin Meier 
methodology. Comparisons in these studies were between two groups of people; one group 
received traditional chemotherapy combinations while the other group received the same 
combination with the addition of Portrazza. These were both open label, randomized, controlled 
phase III trials8,9. For the study involving structures of the lower GI tract the outcome measured 
was objective tumor response rate. This was measured using the Response Evaluation Criteria in 
Solid Tumors, Version 1.0. All member of this trial received Portrazza in addition to FOLFOX 
agents. The comparison was between one group which had a KRAS wildtype gene mutation and 
another group which had a KRAS mutant gene mutation. This was a single arm, multicenter, 
phase II study3.
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Key words used in searches were “lung cancer”, “colon cancer”, “Portrazza”, 
“chemotherapy”, and “stage IV”. All articles were published in American English. They were 
searched on PubMed and Cochrane Library Collection and selected based on their clinical 
relevance to PAs and whether they included patient oriented outcomes. All articles were 
published and the research was done by the author of this paper. Inclusion/ exclusion criteria is 
included on Table 1. Statistics used include ARR, RRR, NNT, p-value, and confidence intervals. 
Demographic information from the trials is included in Table 1.
Table 1
Study Type # of 
pts
w/
d
Age Inclusion criteria Exclusion 
criteria
Intervention
Elez, E, 
Hendlisz, A,
Delaunoit, 
T. 
(2016)3
Single arm 
multicenter 
phase II 
study
25 0 >18 Advanced 
unresectable or 
metastatic 
adenocarcinoma 
of the colon or 
rectum, life 
expectancy > 6 
months, an 
Eastern 
Cooperative 
Oncology Group
performance 
status < 2, 
adequate organ 
function. 
Prior systemic
chemotherapy 
for locally 
advanced 
unresectable 
CRC, prior 
radiotherapy 
to >25% of 
bone marrow, 
documented 
or 
symptomatic 
brain 
metastasis
Addition of 
Necitumumab 
to FOLFOX6 
agents.
Thatcher, N,
Hirsch, FR, 
Luft. 
(2015)9
Open label, 
randomized 
controlled 
phase 3 
trial.
1093 77 >18 Adequate organ 
function of 0-2 
as defined by the
Eastern 
Cooperative 
Oncology. 
Availability of 
archived tumor 
tissue for the 
analysis of 
biomarkers.
Previous 
chemotherapy 
within 4 
weeks of trial.
Chest 
irritation 
within 12 
weeks of the 
trial. Brain 
metastasis
Addition of 
Necitumumab 
to 
Gemcitibine 
and Cisplatin.
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Paz-Ares L, 
Mezger J, 
Ciuleanu 
TE. 
(2015)8
Open label 
randomized 
controlled 
phase 3 
trial. 
633 54 >18 No previous 
chemotherapy, 
adequate organ 
function, 
measurable 
disease as 
defined by 
RECIST 1.0 
criteria, 
histologically 
confirmed stage 
IV cancer.
Brain 
metastasis, 
third-space 
fluid 
retention, 
peripheral 
neuropathy 
grade 2 or 
worse, major 
surgery 
therapy within
4 weeks prior. 
Addition of 
Necitumumab 
to Pemetrexed
and Cisplatin.
RESULTS
In the trial composed by Paz- Ares, et al, there was not sufficient evidence to support the 
use of Portrazza as a more effective treatment for late stage lung cancer. In this trial 315 patients 
received the experimental combination of medicine (Portrazza, Cisplatin, and Pemetrexed) while
318 received the traditional chemotherapy regiment (Cisplatin and Pemetrexed). Unfortunately, 
the results were not promising, as the authors remark, “there was no significant difference in 
overall survival between treatment groups”8. The median survival of the experimental group was 
11.3 months while median survival of the group receiving traditional therapy was 11.5 months. 
P-value in this study was 0.968. Data was still collected between the two groups and results are 
recorded in Table 2. The average survival time was not the only factor which was measured. 
Mortality rate at one year was also measured and this showed that the experimental group 
actually had a lower rate than the control. Based on the mortality rate at one year the relative risk
reduction of the experiment group was 11% while the absolute risk reduction was 2.5%. There 
were 79 participants in the experimental group still living after one year compared to 72 of the 
control group. The numbers needed to treat in this experiment was 40, meaning 40 patients 
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would need to receive the experimental medicine in order to attain one more beneficial outcome. 
The CER and EER were measured based on the number of patients who were still living after 
one year.
Further trials for this medicine were warranted and are discussed later in this paper. 
Despite the difference in average survival times in first trial it is important to note that the 
authors do feel that their data is still useful. An important factor in this trial is that the histology 
of disease being treated was non-squamous non-small cell lung cancer while in the following 
trial patients with squamous non-small cell were being treated. It is possible that one type of cell 
is more responsive to the experimental treatment than other types. 
Table 2
Control 
Event Rate
(CER)
Experimental
Event Rate 
(EER)
Relative 
Risk 
Reduction
Absolute 
Risk 
Reduction 
Numbers
Needed 
to Treat
95%Confidence 
Interval
22.6% 25.1% 11% 2.5% 40 Control 43-54%
Exp. 42-53%
In the trial conducted by Thatcher, et al, the authors again had two sample groups. The 
first group had 545 patients who received Portrazza in addition to Gemcitabine and Cisplatin. 
The second group had 548 patients and received only Gemcitabine and Cisplatin. The results 
were more promising in this study. Authors concluded that “the addition of Necitumumab to 
Gemcitabine and Cisplatin chemotherapy improves overall survival in patients…and represents a
new first line treatment option for this disease”9. The average survival time in the control group 
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was 9.9 months compared to 11.5 months in the experimental group. As with the first trial the 
data calculated in this paper was based not on the average survival time, but on the number of 
deaths measured at one year into the experiment. Again the experimental group came out on top 
with better survival rates. The relative risk reduction for this trial was 21%. Absolute risk 
reduction was 4%. The number needed to treat was 25, meaning that 25 patients would need to 
be treated in order for one additional beneficial outcome to be obtained. P-value when measuring
average time of survival was 0.019. It is safe to say that the numbers display a benefit in using the
experimental medicine. There were 127 patients living at one year in the experimental group 
compared to 106 in the control group. Table 3 summarizes this data. The event measured for 
EER and CER in the table was number of patients alive after one year. 
Table 3
Control Event
Rate (CER)
Experimental 
Event Rate 
(EER)
Relative Risk 
Reduction
(RRR)
Absolute 
Risk 
Reduction
(ARR) 
Numbers
Needed 
to Treat
95% Confidence 
Interval
19% 23% 21% 4% 25 Control 13-20%
Exp. 16-24%
The third trial for this medication, performed by Elez, et al, was designed differently than
the first two. It was a single arm phase II study and rather than investigating lung cancer the 
experimental and control groups had stage IV colorectal cancer. All patients in this trial received 
Portrazza in addition to FOLFOX6 chemotherapy. One variable which the designers of this trial 
were aiming to measure is whether or not certain genetic mutations in humans are more 
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responsive to Portrazza than others. This is useful because as we advance research into cancer 
treatment we may be able to tailor medication to the specific patient and their genetic makeup. 
The results of this trial demonstrated that those who had the KRAS wild type gene mutation had 
better outcomes than those who had a KRAS mutant gene mutation3. For the purpose of data 
collection in this trail the experimental group consists of patients with the wild type gene 
mutation and those in the control group had the mutant type mutation. Total experimental 
participants were 16 patients and the total control group was 9 patients. 
The results show that those with the wild type mutation had a better partial response rate. 
10 members of the trial receiving with the wild type mutation had a partial response rate 
compared to 5 members who had the mutant type mutation. This rate is what was measured to 
obtain the values in table 4. The control event rate was 55% and experimental event rate was 
62.5%. The relative benefit increase was 12.6% and the absolute benefit increase was 7.0%. The 
numbers needed to treat was 14, meaning 14 patients needed to be treated to obtain one 
additional favorable outcome. P-value was not reported in this study but the confidence interval 
for the experimental group was 79-100% and for the control group was 66-100%3.
Table 4
Control 
Event Rate
Experimental
Event Rate
Relative 
Benefit 
Increase
Absolute 
Benefit 
Increase
Numbers
Needed 
to Treat
95% Confidence 
Interval
55% 62.5% 12.6% 7.0% 14 Control 66-100%
Exp. 79-100%
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There are a number of adverse side effects of Portrazza which the authors of these studies
measured. In particular, the first two trials, which examined non-small cell lung cancer, measured
the rates of a grade 3 rash in their participants. These rates were used to then calculate the 
numbers needed to harm for both of the clinical trials. In the trial by Paz Ares, et al, 44 members 
of the experimental group developed a rash compared to only one member of the control group8. 
The control event rate was .00314, experimental event rate was .140, and absolute risk increase .
136. Numbers needed to harm for this study was 7, meaning for every 7 patients treated with 
Portrazza, one more will be affected by an adverse reaction. For the trial performed by Thatcher, 
et al, 38 members of the experimental group developed a grade 3 rash compared with only two 
members of the control9. The control event rate was .00365, experimental event rate was .07, and
absolute benefit increase .067. The numbers needed to harm was 15, meaning 15 patients would 
need to be treated for one additional patient to have an adverse reaction of a grade 3 rash. This 
data is summarized in Table 5.
Table 5
Control Event 
Rate (CER)
Experimental 
Event Rate 
(EER)
Absolute Risk 
Increase (ARI)
Numbers 
Needed to Harm 
(NNH)
Paz-Ares8 .00314 .140 .136 7
Thatcher, N9 .00365 .07 .067 15
    
Discussion
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This systematic review investigated two randomized control trials and one single arm 
phase II study. The results were for the most part encouraging. Overall the addition of Portrazza 
to a traditional chemotherapy increased percentage of living patients after one year and two years
of treatment. It also demonstrated that patients with different genetic mutations may be more 
responsive to treatment with this medication. There were no obvious outliers in these studies.
Sample size and drop-out rates are two factors which limited these clinical trials. Given 
the high rate of cancer diagnoses in the US it would be useful to have more trials with bigger 
pools of participants in the future. Additionally, a number of group members in each trial 
dropped out due to adverse drug reactions from the experimental medicine. This lowered the 
sample size. The trial measuring treatment of colon cancer was limited in both size and 
geographic location. The sample groups were very small and were taken in Europe where 
lifestyle and diet can both have different effects on the body when compared to American 
culture. Despite any short comings of these trials Portrazza was approved by the FDA in 2015 for
use in squamous non-small cell lung cancer7. 
Portrazza is currently manufactured for an 800mg dose given intravenously over 60 
minutes. For a three week cycle of therapy it is to be given on days 1 and 8. Though the most 
common side effect is a rash there is a warning with this product that cardiopulmonary arrest and
hypomagnesemia are both potential adverse effects5. This is due to some patients experiencing 
these in the clinical trials. One of the trials in this paper discussed using Portrazza in colorectal 
cancer however it is currently only marketed for use is in squamous non-small cell lung cancer. 
Pregnant women are advised against taking Portrazza. There are no studies in regards to breast 
feeding while on this medication, but women are advised against doing this until at least three 
months after their last dose5. There are no studies regarding using Portrazza in the pediatric 
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population. There is currently no evidence that poor hepatic or renal function would be 
contraindications to taking this medication. There is a risk of venous thromboembolism with 
Portrazza. Manufacturers recommend discontinuing the medication immediately if patients 
develop an embolism5.
Conclusion
The data collected in these three trials indicates that yes, Portrazza is effective in treating 
Stage IV metastatic cancer. There is however a catch. It is only effective in squamous non-small 
cell lung cancer. Two of the trials were performed on other types of cancer, and the medication 
did not prove effective in prolonging life in non-squamous non-small cell. There is conclusive 
evidence that those with a KRAS wildtype gene mutation may have a better outcome using 
Portrazza than those who do not. Future studies may be more effective if they include patients 
who have earlier stages of the disease. This could help tell us the efficacy of fully curing patients.
In the last few decades we have seen massive strides in research behind the pathophysiology of 
cancer, treatments of this disease, and more effective ways of managing patient care. Portrazza is
another step in the right direction in our fight against this tragic disease.
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